Related Experiment Video
Updated: Mar 17, 2026

Evaluation of Respiratory System Mechanics in Mice using the Forced Oscillation Technique
Published on: May 15, 2013
Respiratory System Disease
Danielle M Goetz1, Shipra Singh1
1Pediatric Pulmonology, Jacobs School of Medicine, Women & Children's Hospital of Buffalo, State University of New York, 219 Bryant Street, Buffalo, NY 14222, USA.
Abstract:
Respiratory system involvement in cystic fibrosis is the leading cause of morbidity and mortality. Defects in the cystic fibrosis transmembrane regulator (CFTR) gene throughout the sinopulmonary tract result in recurrent infections with a variety of organisms including Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and nontuberculous mycobacteria. Lung disease occurs earlier in life than once thought and ideal methods of monitoring lung function, decline, or improvement with therapy are debated. Treatment of sinopulmonary disease may include physiotherapy, mucus-modifying and antiinflammatory agents, antimicrobials, and surgery. In the new era of personalized medicine, CFTR correctors and potentiators may change the course of disease.
Insights
Cystic fibrosis (CF) primarily affects the respiratory system, leading to infections and lung disease. Emerging CFTR-targeted therapies offer new hope for managing this complex genetic disorder.
Area of Science:
- Pulmonology
- Genetics
- Infectious Diseases
Background:
- Cystic fibrosis (CF) is a genetic disorder primarily impacting the respiratory system, causing significant morbidity and mortality.
- Defects in the cystic fibrosis transmembrane regulator (CFTR) gene lead to sinopulmonary infections by various pathogens, including Pseudomonas aeruginosa.
- Early-onset lung disease in CF necessitates effective monitoring and treatment strategies.
Purpose of the Study:
- To review the current understanding of sinopulmonary disease in cystic fibrosis.
- To discuss current and emerging treatment modalities for CF-related lung disease.
- To highlight the potential of personalized medicine, specifically CFTR modulators, in altering disease trajectory.
Main Methods:
- Literature review of sinopulmonary involvement in cystic fibrosis.
- Analysis of current therapeutic approaches including physiotherapy, medications, and surgery.
- Examination of the role of novel CFTR correctors and potentiators.
Main Results:
- Respiratory system involvement is the primary driver of morbidity and mortality in CF.
- Recurrent sinopulmonary infections are a hallmark of the disease, caused by pathogens like P. aeruginosa.
- Debate exists regarding optimal methods for monitoring lung function decline or improvement.
Conclusions:
- Effective management of CF sinopulmonary disease requires a multi-faceted approach.
- Personalized medicine, particularly CFTR modulators, represents a significant advancement in CF treatment.
- These novel therapies hold the potential to fundamentally change the course of cystic fibrosis lung disease.
Related Concept Videos
The Respiratory System
Respiratory System Abnormal Finding I: Inspection and Percussion
Inspection Findings
During an inspection, several findings may suggest the presence of respiratory distress or disease. Pursed-lip breathing, where exhalation is slowed by...
Other Pulmonary Disorders
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Breathing
Overview of Respiratory System
What is the Respiratory System?
The respiratory system consists of a series of organs responsible for taking in oxygen and expelling carbon dioxide. The primary function of the respiratory system is to...

